[Pubmed] Elevated C1s/C1-INH in serum and plasma of myasthenia gravis patients

[RSS-Bot]

J Neuroimmunol. 2024 Sep 3;396:578447. doi: 10.1016/j.jneuroim.2024.578447. Online ahead of print.

ABSTRACT

Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder where acetylcholine receptor (AChR) antibodies induce membrane attack complex formation at the muscle membrane. The C1-inhibitor (C1-INH) regulates the classical pathway and is a promising marker in other autoimmune disorders. Treatment options for AChR antibody MG include complement inhibitors; nevertheless, the early pathway activation in MG remains unclear. Serum and plasma C1s-C1-INH levels were higher in MG patients than in matched healthy controls, supporting early classical pathway activation in most MG patients. These findings allow prospective validation studies of activated C1s as a putative treatment target and potential accompanying biomarker in MG.

PMID:39255718 | DOI:10.1016/j.jneuroim.2024.578447


Source: https://pubmed.ncbi.nlm.nih.gov/3925571 ... t9+e462414